AngioDynamics Promotes William Appling to Senior Vice President of Research and Development.QUEENSBURY, N.Y. -- AngioDynamics (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ANGO ANGO Algemene Nederlandse Gehandicapten Organisatie (Dutch: Equal Opportunities for Persons with Disabilities) ), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. , announced today that it has promoted its vice president of research, William Appling, 44, to the position of senior vice president of research and development, effective immediately. In his new role, Mr. Appling will lead the continued development of the entire portfolio of AngioDynamics' products, including the NeverTouch[TM] VenaCure[R] procedure kit and the Profiler Balloon Catheter balloon catheter n. A catheter with an inflatable balloon at its tip, used especially to expand a partially obstructed blood vessel or bodily passage and to measure blood pressure in a blood vessel. Also called balloon-tip catheter. product lines. Mr. Appling will also continue to oversee AngioDynamics' IP portfolio that includes more than 135 issued US patents, foreign counterparts, 53 pending applications, and more than 80 issued and pending trademarks. He will also continue to head the Company's due diligence Research; analysis; your homework. This term has caught on in all industries, because it sounds so "wired." Who would want to do analysis or research when they can do due diligence. See wired. evaluations of outside technology acquisition opportunities. Mr. Appling will remain a member of the corporate executive management team, reporting directly to Robert D. Mitchell, executive vice president and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . Prior to this promotion, Mr. Appling had served as the Company's vice president of research since 2002. Mr. Appling was the vice president of product development at AngioDynamics from 1997 until 2002 and joined the Company as the manager of catheter operations when AngioDynamics was a division of E-Z-EM, Inc. in 1988. "With his wealth of experience and proven track record, Bill has brought a tremendous level of industry expertise and leadership to AngioDynamics over the past two decades," said Robert Mitchell, AngioDynamics' chief operating officer. "Bill has played an instrumental role in our ability to quickly commercialize products in our R&D pipeline, allowing the Company to strategically respond to rapid changes in the market. His promotion should strengthen our research and development abilities, and his commitment to our technology, combined with his skill set, should have a significant impact on our worldwide operations. We look forward to his continued contributions." Mr. Appling has more than 20 years of experience with research, development, and the manufacture of medical devices. Prior to joining AngioDynamics, Mr. Appling held the roles of manager of product development and manager of catheter operations at E-Z-EM, Inc. Before this, Mr. Appling was a product development engineer for Glen Falls, NY based NAMIC NAMIC National Association of Mutual Insurance Companies NAMIC National Association for Multi-Ethnicity in Communications NAMIC National Association of Minorities in Cable Incorporated. Mr. Appling began his career in the medical device industry with roles at American Edwards Labs and Sheridan Catheter Corporation. About AngioDynamics AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation Radiofrequency ablation (RFA) A technique for removing a tumor by heating it with a radiofrequency current passed through a needle electrode. Mentioned in: Liver Cancer, Prenatal Surgery systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. products, embolization embolization /em·bo·li·za·tion/ (em?bo-li-za´shun) 1. the process or condition of becoming an embolus. 2. therapeutic introduction of a substance into a vessel in order to occlude it. products and venous products. Safe Harbor The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion